Abstract 3123
Background
The use of ICTs has become widespread in recent years. There is little information available in Turkey about the level of usage of ICTs for and by cancer patients.
Methods
This descriptive study was conducted to determine the level of ICTs use and patterns of preferences among cancer patients in Ankara, Turkey. The survey was started on March 2019 and the data collection process is continuing. The sample size was determined as 334 and 173 patients were reached. In data collection, a questionnaire including 38 questions about patient demographics, use of cell phones, the interest of patients in using ICTs to receive information about cancer, and the interest of patients in using ICTs to communicate with health care providers about cancer. The study was approved by university research and ethics committees and informed consent were obtained from patients.
Results
The mean age of the participants was 60.19±12.60 (range 27-89 years), 68.2% were female, 45.7% were primary school graduate. Mean duration of diagnosis was 24.12± 28.56 (range 1-120) months, 26% were breast cancer, 21.4 % had metastasis. Of the total, 78.6% of participants reported that they had access to the internet. The ICTs used at least once a week was found to be respectively WhatsApp (63.5%), Facebook (60.7%), instagram (34.1%), youtube (32.3%) and short message service (SMS) text messaging (31.7%). With regard to the preferences on how patients would like to use ICTs to receive information about diseases, Internet (63.0%), SMS (21.3%) and WhatsApp (19.6%) were widely reported as interesting communication channels. Participants 61.8% rely on information obtained through ICTs. Internet (36.4%), SMS (17.3%) followed by WhatsApp (15.0%, 26/173) were reported as the preferred ICTs through which patients would like to ask health providers about diseases. Adjusted regression analysis showed that patients aged between 45-64 years were more likely to be interested in receiving information through SMS than the oldest group.
Conclusions
In this study, we have determined that SMS text messaging presented the highest rate of interest for receiving information and communicating with health providers, followed by WhatsApp.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3252 - Genes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma
Presenter: Fernanda Costa Svedman
Session: Poster Display session 3
Resources:
Abstract
5545 - Phase Ib/II Study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy
Presenter: Jessica Hassel
Session: Poster Display session 3
Resources:
Abstract
5213 - Genomic landscape of primary malignant melanoma of esophagus
Presenter: Jie Dai
Session: Poster Display session 3
Resources:
Abstract
2716 - A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
3550 - ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy
Presenter: Marcus Butler
Session: Poster Display session 3
Resources:
Abstract
1645 - PRIME002 - Early phase II study of Azacitidine and Carboplatin priming for Avelumab in patients with advanced melanoma who are resistant to immunotherapy
Presenter: Andre Van Der Westhuizen
Session: Poster Display session 3
Resources:
Abstract
4440 - Pembrolizumab (pembro) Plus Lenvatinib (len) for First-Line Treatment of patients (pts) With Advanced Melanoma: Phase 3 LEAP-003 Study
Presenter: Alexander Eggermont
Session: Poster Display session 3
Resources:
Abstract
3454 - Proof of concept study with the histone deacetylase inhibitor vorinostat in patients with resistant BRAFV600 mutated advanced melanoma
Presenter: Sanne Huijberts
Session: Poster Display session 3
Resources:
Abstract
1832 - A phase Ia/Ib clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary anti-tumor activity of FCN-159 in patients with advanced melanoma harboring NRAS-aberrant (Ia) and NRAS-mutation (Ib).
Presenter: Lu Si
Session: Poster Display session 3
Resources:
Abstract
3996 - A Phase I Clinical Trial Investigating the Therapeutic Cancer Vaccine UV1 in Combination with Pembrolizumab as First-Line Treatment of Patients with Malignant Melanoma
Presenter: Sanjiv Agarwala
Session: Poster Display session 3
Resources:
Abstract